iTeos Therapeutics and GSK have begun the GALAXIES Lung-301 Phase III clinical trial of belrestotug in combination with dostarlimab for the treatment of non-small cell lung cancer (NSCLC).
The double-blind, placebo-controlled study aims to compare the combination of belrestotug and dostarlimab against placebo plus pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will enrol around 1,000 patients in North and South America, Asia and Europe.
Progression-free survival and overall survival are the trial’s primary endpoints.
Participants will be randomised at a 1:1 ratio to receive either an intravenous infusion of the belrestotug plus dostarlimab regimen or placebo plus pembrolizumab.
Last month, iTeos published interim analysis data from the Phase II GALAXIES Lung-201 study showing that the belrestotug-dostarlimab combination surpassed the pre-defined efficacy criteria for clinically relevant activity.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also demonstrated an acceptable safety profile consistent with the TIGIT:PD-1 class.
In addition, the treatment regimen offered “clinically meaningful” tumour reduction at every dose compared with dostarlimab monotherapy.
iTeos Therapeutics president and CEO Michel Detheux said: “With the initiation of the first Phase III study for belrestotug, we are entering a monumental stage in our journey to develop a world-leading oncology company.
“Nearly 70% of patients with first-line PD-L1 high non-small cell lung cancer rely upon a chemotherapy-free regimen. We believe belrestotug + dostarlimab are poised to potentially advance the therapeutic regimen in this setting and establish new benchmarks.
“Based on our high-quality doublet exceeding its pre-defined efficacy criteria for clinically relevant activity in an interim assessment from the Phase II GALAXIES Lung-201 study, we believe initiating the Phase III programme with this patient population will serve as the foundation to our broader strategy and marks our first step in building a franchise.”
Based in Massachusetts, iTeos currently has three clinical-stage programmes targeting novel and validated immunosuppressive pathways in its pipeline.
